For research use only. Not for use in humans.

Belimumab (Anti-TNFSF13B / BAFF / CD257)

Synonyms: TNFSF13B, CD257

Belimumab (Anti-TNFSF13B / BAFF / CD257) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research. MW : 144.56 kDa.

Belimumab (Anti-TNFSF13B / BAFF / CD257)

Click to purchase the isotype control of Belimumab (Anti-TNFSF13B / BAFF / CD257)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Belimumab (Anti-TNFSF13B / BAFF / CD257) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research. MW : 144.56 kDa.

Product Details

CAS No. 356547-88-1
Molecular Weight 144.56 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06191887 RECRUITING Drug: Bendamustine|Drug: Cyclophosphamide|Drug: Fludarabine B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Small Lymphocytic Lymphoma; Refractory Transformed Chronic Lymphocytic Leukemia Mayo Clinic 2024-03-18 PHASE1
NCT07771361 NOT_YET_RECRUITING Non-Hodgkin Lymphoma Refractory/ Relapsed; Multiple Myeloma Refractory; Multiple Myeloma in Relapse; Non-Hodgkin Lymphoma, B-cell; Non-Hodgkin Lymphoma; Non-Hodgkin Lymphoma (NHL); Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma; Multiple Myeloma in Remission Luminary Therapeutics 2026-12 PHASE2
NCT07729995 NOT_YET_RECRUITING Rheumatoid Arthritis (RA); Systemic Lupus Erthematosus (SLE); Dermatomyositis (DM); Systemic Sclerosis (SSc) Luminary Therapeutics 2026-10 PHASE1
NCT06716606 RECRUITING Drug: Belimumab Connective Tissue Diseases GlaxoSmithKline 2024-12-12 PHASE3
NCT07259070 RECRUITING Drug: BAFF-R CAR-T DLBCL; CLL; FL; MCL; WM; MZL Institute of Hematology & Blood Diseases Hospital, China 2025-11-29 PHASE1; PHASE2
NCT05878717 RECRUITING Systemic Sclerosis Associated Interstitial Lung Disease; Scleroderma, Systemic GlaxoSmithKline 2023-09-13 PHASE2; PHASE3

(data from https://clinicaltrials.gov, updated on 2026-02-13)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.